- Home
- TSLX vs ZLAB Comparison
TSLX vs ZLAB Comparison
Compare TSLX & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSLX | ZLAB |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TSLX | ZLAB |
|---|---|---|
| Price | $21.55 | $17.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $23.50 | ★ $57.22 |
| AVG Volume (30 Days) | 430.2K | ★ 989.7K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $464,512,000.00 | $441,629,000.00 |
| Revenue This Year | N/A | $30.20 |
| Revenue Next Year | N/A | $34.71 |
| P/E Ratio | $10.66 | ★ N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $18.58 | $16.82 |
| 52 Week High | $25.17 | $44.34 |
Technical Indicators
Market Signals| Indicator | TSLX | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 31.02 |
| Support Level | $21.62 | $16.82 |
| Resistance Level | $22.00 | $18.67 |
| Average True Range (ATR) | 0.29 | 0.60 |
| MACD | -0.06 | 0.13 |
| Stochastic Oscillator | 3.01 | 33.24 |
Price Performance
Historical ComparisonAbout TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.